2014 Press Releases

2014 | 2013 | 2012
Keyword Search
 
DateTitle 
09/05/14Depomed Summary Judgment Motion Granted in Suit against FDA Seeking Orphan Drug Exclusivity for Gralise® (Gabapentin)Printer Friendly Version
09/04/14Depomed Announces Pricing of Upsized $300 Million Convertible Senior Notes Due 2021Printer Friendly Version
09/02/14Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021Printer Friendly Version
08/25/14Depomed To Present At Morgan Stanley 2014 Global Healthcare ConferencePrinter Friendly Version
08/19/14Depomed Prevails in Gralise® ANDA Litigation Blocking Generic Entry Until 2024Printer Friendly Version
08/06/14Depomed Reports Second Quarter 2014 Financial ResultsPrinter Friendly Version
08/04/14Depomed Announces Appointment of R. Scott Shively as Chief Commercial OfficerPrinter Friendly Version
07/25/14Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014Printer Friendly Version
07/17/14Depomed Announces District Court Order in ANDA LitigationPrinter Friendly Version
07/16/14Depomed Announces Appointment of Srinivas G. Rao, MD, PhD, as Chief Medical OfficerPrinter Friendly Version
06/18/14Depomed To Present AT JMP Securities 2014 Healthcare ConferencePrinter Friendly Version
06/10/14Depomed to Present at Wells Fargo 2014 Healthcare ConferencePrinter Friendly Version
05/28/14Mallinckrodt New Drug Application For MNK-155 Accepted For Review By FDAPrinter Friendly Version
05/27/14Depomed To Present At Jefferies 2014 Global Healthcare ConferencePrinter Friendly Version
05/09/14Depomed To Present At Bank of America Merrill Lynch Healthcare Conference And UBS Global Healthcare ConferencePrinter Friendly Version
05/08/14Depomed Reports First Quarter 2014 Financial ResultsPrinter Friendly Version
04/30/14Depomed To Report First Quarter Fiscal Year 2014 Financial Results On Thursday, May 8, 2014Printer Friendly Version
04/14/14Depomed Announces Settlements with Two Gralise® ANDA FilersPrinter Friendly Version
03/12/14Depomed Earns $10 Million Milestone for FDA Approval of Mallinckrodt's XARTEMIS™ XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII)Printer Friendly Version
03/12/14Depomed Reports Fourth Quarter and Full Year 2013 Financial ResultsPrinter Friendly Version
03/10/14Depomed To Report Fourth Quarter Fiscal Year 2013 Financial Results On Wednesday, March 12, 2014Printer Friendly Version
03/05/14Depomed To Present At The 26th Annual ROTH Conference On Monday, March 10, 2014Printer Friendly Version
02/25/14Depomed Reports Preliminary Q4 2013 and Full Year Financial InformationPrinter Friendly Version
02/20/14Depomed To Present At Upcoming Healthcare ConferencesPrinter Friendly Version
01/29/14Depomed Announces Favorable Markman Ruling in GRALISE® Patent LitigationPrinter Friendly Version

DEPO (Common Stock)

Exchange
NASDAQ CM
Price
$15.16
Change (%)
 - 0.03 (0.20%)
Volume
1,426,381
Market Cap
$888,163,760

Data as of 10/01/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Powered By EDGAR Online, Inc.